Based on 410 progression-free survival events , progression-free survival was improved in patients assigned to pembrolizumab 2 mg/kg ( HR 057 , 95 % CI 045-073 ; p < 00001 ) and those assigned to pembrolizumab 10 mg/kg ( 050 , 039-064 ; p < 00001 ) compared with those assigned to chemotherapy .